Molecular chaperones in mammary cancer growth and breast tumor therapy

Journal of Cellular Biochemistry

Volumn 113, Issue 4, 2012, Pages 1096-1103

  Calderwood, Stuart K ^a   Gong, Jianlin ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BREAST; CANCER; CHAPERONE; GROWTH; MOLECULAR; THERAPY

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; TUMOR ANTIGEN; TUMOR VACCINE;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; CARCINOGENESIS; CELL POPULATION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); IMMUNE RESPONSE; IMMUNOSURVEILLANCE; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SENESCENCE; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MOLECULAR CHAPERONES;

EID: 84857509287     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23461     Document Type: Article

References (46)

1. Agoff SN, Hou J, Linzer DI, Wu B,. 1993. Regulation of the human hsp70 promoter by p53. Science 259: 84-87.
2. Calderwood SK, Xie Y, Wang X, Khaleque MA, Chou SD, Murshid A, Prince T, Zhang Y,. 2010. Signal transduction pathways leading to heat shock transcription. Signal Transduction Insights 2: 13-24.
3. Campisi J,. 2005. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120: 513-522.
4. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, Borg C, Apetoh L, Rebe C, Ghiringhelli F,. 2010. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 120: 457-471.
5. Chouaib S, Thiery J, Gati A, Guerra N, El Behi M, Dorothee G, Mami-Chouaib F, Bellet D, Caignard A,. 2002. Tumor escape from killing: Role of killer inhibitory receptors and acquisition of tumor resistance to cell death. Tissue Antigens 60: 273-281.
6. Ciocca DR, Calderwood SK,. 2005. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperon 10: 86-103.
7. Dai C, Whitesell L, Rogers AB, Lindquist S,. 2007. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130: 1005-1018.
8. Ellis RJ,. 2007. Protein misassembly: Macromolecular crowding and molecular chaperones. Adv Exp Med Biol 594: 1-13.
9. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R,. 1993. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75: 1027-1038.
10. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G,. 2006. Heat shock proteins 27 and 70: Anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5.
11. Gong J,., Calderwood SK,. Elevated levels of HSPs in tumor initiating cells (In Preparation).
12. Gong J, Zhang Y, Durfee J, Weng D, Liu C, Koido S, Song B, Apostolopoulos V, Calderwood SK,. 2010. A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use. J Immunol 184: 488-496.
13. Gray PJ, Jr, Prince T, Cheng J, Stevenson MA, Calderwood SK,. 2008. Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer 8: 491-495.
14. Hanahan D, Weinberg RA,. 2000. The hallmarks of cancer. Cell 100: 57-70.
15. Hanahan D, Weinberg RA,. 2011. Hallmarks of cancer: The next generation. Cell 144: 646-674.
16. Jaskelioff M, Song W, Xia J, Liu C, Kramer J, Koido S, Gendler SJ, Calderwood SK, Gong J,. 2009. Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene. Oncogene 28: 4225-4236.
17. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ,. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
18. Kaur P, Nagaraja GM, Asea A,. 2011. Combined lentiviral and RNAi technologies for the delivery and permanent silencing of the hsp25 gene. Methods Mol Biol 787: 121-136.
19. Khaleque MA, Bharti A, Sawyer D, Gong J, Benjamin IJ, Stevenson MA, Calderwood SK,. 2005. Induction of heat shock proteins by heregulin beta1 leads to protection from apoptosis and anchorage-independent growth. Oncogene 24: 6564-6573.
20. Khaleque MA, Bharti A, Gong J, Gray PJ, Sachdev V, Ciocca DR, Stati A, Fanelli M, Calderwood SK,. 2008. Heat shock factor 1 represses estrogen-dependent transcription through association with MTA1. Oncogene 27: 1886-1893.
21. Liang J, Wan M, Zhang Y, Gu P, Xin H, Jung SY, Qin J, Wong J, Cooney AJ, Liu D, Songyang Z,. 2008. Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Nat Cell Biol 10: 731-739.
22. Lindquist S, Craig EA,. 1988. The heat shock proteins. Ann Rev Genet 22: 631-637.
23. Mambula SS, Calderwood SK,. 2006. Heat induced Hsp70 release from prostate carcinoma cells involves both active secretion and passive release from necrotic cells. Int J Hyperthermia 22: 575-585.
24. Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR,. 2003. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 171: 4054-4061.
25. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK, Kumar R,. 2001. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3: 30-37.
26. Min JN, Huang L, Zimonjic DB, Moskophidis D, Mivechi NF,. 2007. Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene 26: 5086-5097.
27. Murshid A, Gong J, Stevenson MA, Calderwood SK,. 2011. Heat shock proteins and cancer vaccines: Developments in the past decade and chaperoning in the decade to come. Expert Rev Vaccines 10: 1553-1568.
28. Neckers L,. 2002. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8: S55-S61.
29. O'Callaghan-Sunol C, Gabai VL, Sherman MY,. 2007. Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res 67: 11779-11788.
30. Pardoll D,. 2003. Does the immune system see tumors as foreign or self? Annu Rev Immunol 21: 807-839.
31. Paul C, Manero F, Gonin S, Kretz-Remy C, Virot S, Arrigo AP,. 2002. Hsp27 as a negative regulator of cytochrome C release. Mol Cell Biol 22: 816-834.
32. Powers MV, Clarke PA, Workman P,. 2008. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 14: 250-262.
33. Powers MV, Jones K, Barillari C, Westwood I, van Montfort RL, Workman P,. 2011. Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone? Cell Cycle 9: 1542-1550.
34. Queitsch C, Sangster TA, Lindquist S,. 2002. Hsp90 as a capacitor of phenotypic variation. Nature 417: 618-624.
35. Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J, Jaattela M,. 2005. Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev 19: 570-582.
36. Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinson SE, Schnitt SJ, Whitesell L, Tamimi RM, Lindquist S, Ince TA,. 2011. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci USA 108: 18378-18383.
37. Sherman MY, Meng L, Stampfer M, Gabai VL, Yaglom JA,. 2010. Oncogenes induce senescence with incomplete growth arrest and suppress the DNA damage response in immortalized cells. Aging Cell 10: 949-961.
38. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, Popescu NC, Weinberg RA,. 2002. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 99: 12606-12611.
39. Trepel J, Mollapour M, Giaccone G, Neckers L,. 2010. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549.
40. Visvader JE,. 2009. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 23: 2563-2577.
41. Vogelstein B, Kinzler KW,. 1993. The multistep nature of cancer. Trends Genet 9: 138-141.
42. Wadhwa R, Taira K, Kaul SC,. 2002. An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: What, when, and where? Cell Stress Chaperon 7: 309-316.
43. Weng D, Song B, Durfee J, Sugiyama V, Wu Z, Koido S, Calderwood SK, Gong J,. 2010. Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int J Cancer epub ahead of print.
44. Whitesell L, Lindquist SL,. 2005. HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772.
45. Workman P,. 2004. Altered states: Selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10: 47-51.
46. Zaarur N, Gabai VL, Porco JA, Jr, Calderwood S, Sherman MY,. 2006. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res 66: 1783-1791.